Identification

Name
Lidocaine
Accession Number
DB00281  (APRD00479, DB05291)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem]

Structure
Thumb
Synonyms
  • 2-(Diethylamino)-2',6'-acetoxylidide
  • 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
  • alpha-diethylamino-2,6-dimethylacetanilide
  • Lignocaine
  • α-diethylamino-2,6-dimethylacetanilide
External IDs
ALGRX 3268 / ALGRX-3268 / LSM-3165 / NSC-40030
Product Ingredients
IngredientUNIICASInChI Key
Lidocaine hydrochlorideV13007Z41A6108-05-0YECIFGHRMFEPJK-UHFFFAOYSA-N
Lidocaine hydrochloride anhydrousEC2CNF7XFP73-78-9IYBQHJMYDGVZRY-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
2% Lidocaine Hydrochloride Injection USPSolution20 mgIntravenousHospira, Inc.1987-12-31Not applicableCanada
AgonEazeKitTopicalAlvix Laboratories2016-01-12Not applicableUs
AktenGel35 mg/mLOphthalmicAkorn2008-10-08Not applicableUs
Amniocentesis Tray 1%Liquid1 %Infiltration; SubcutaneousAllegiance Healthcare Corporation1992-12-312000-07-31Canada
AnestheticGel5 g/100gTopicalCosmoceutical Research Center Inc2012-02-18Not applicableUs
Antecubital Cent Venous Catheterization KitLiquid1 %EpiduralArrow International1991-12-311999-07-02Canada
Arthrogram Tray 1%Liquid1 %Intra-articularAllegiance Healthcare Corporation1992-12-312000-07-31Canada
AsteroGel40 mg/gTopicalGensco Laboratories, LLC2016-05-01Not applicableUs
AsteroGel40 mg/gTopicalAll Pharma, Llc2016-05-01Not applicableUs
Atelocollagen ImplantImplant.3 %IntradermalKoken Co. Ltd.1989-12-312005-08-25Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AnestaconJelly20 mg/mLTopicalHi Tech Pharmacal Co., Inc.2001-11-05Not applicableUs
DermacinRx Lido V PakKitTopicalPure Tek Corporation2016-09-22Not applicableUs
DermacinRx PHN PakKitPure Tek Corporation2016-05-17Not applicableUs
DX1 OraGenomic Medicated DNA Collection ScreenKitIt3 Medical Llc2016-05-01Not applicableUs
DX2 OraGenomic Medicated DNA Collection ScreenKitIt3 Medical Llc2016-05-01Not applicableUs
Laryng-O-JetSolution40 mg/mLTopicalAmphastar Pharmaceuticals, Inc.1980-03-062017-01-06Us
LidocaineOintment5 g/100gTopicalLake Erie Medical Dba Quality Care Produts Llc2012-03-12Not applicableUs
LidocaineOintment50 mg/gTopicalPreferreed Pharmaceuticals Inc.2016-10-17Not applicableUs
LidocaineInjection, solution20 mg/mLInfiltration; PerineuralWest Ward Pharmaceutical1972-02-14Not applicableUs
LidocaineOintment50 mg/gTopicalPreferreed Pharmaceuticals Inc.2016-08-23Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Absorbine jr. LidocainePatch246 mg/1TopicalClarion Brands, Llc2017-01-01Not applicableUs
After BurnGel25 mg/mLTopicalTender Corporation2011-04-12Not applicableUs
After Sun Burn Relief Lidocaine Continuous SpraySolution1 %TopicalPrime Enterprises, Inc.2010-04-08Not applicableCanada
After Sun GelGel1 %TopicalWatkins IncorporatedNot applicableNot applicableCanada
After Sun Soothing SprayLiquid; Spray0.5 %TopicalKinesys Pharmaceutical Inc1995-03-17Not applicableCanada
AfterBurnGel2.5 g/100gTopicalTender Corporation2011-04-122016-11-03Us
AfterburnGel0.5 %TopicalTender Corporation1995-12-31Not applicableCanada
Aftersun Cooling CVSGel.5 g/100mLTopicalCvs Health2014-11-11Not applicableUs
Alcoholada Pain RelievingGel5 mg/mLTopicalAruba Aloe Balm, Nv2017-06-10Not applicableUs
AlocaneGel4 %TopicalProduct QuestNot applicableNot applicableCanada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AccucaineInjection, solution10 mg/mLInfiltrationAsclemed Usa, Inc.1972-09-28Not applicableUs
Apicaine-XOintment.05 g/gTopicalMedicap Laboratories Inc.2015-12-122016-02-19Us
CidalEazeCream30 mg/gTopicalAlvix Laboratories2015-08-112018-09-30Us
DermacinRx LidotralCream38.8 mg/gTopicalPure Tek Corporation2015-12-03Not applicableUs
EhaLotion4 g/mLTopicalAsclemed Usa, Inc.2016-06-07Not applicableUs
Lido RxGel30 mg/gTopicalGensco Laboratories, LLC2013-03-01Not applicableUs
LidocaineOintment2.5 g/50gTopicalMartin Ekwealor Pharmaceuticals, Inc.2017-03-04Not applicableUs
LidocaineOintment10 1/1TopicalIt3 Medical, Llc2017-01-012017-04-14Us
LidocaineOintment5 g/100gTopicalTwo Hip Consulting, Llc2016-03-25Not applicableUs
Lidocaine HClCream30 mg/gTopicalPure Tek Corporation2011-06-13Not applicableUs
International/Other Brands
After Burn Double Strength Gel / After Burn Double Strength Spray / After Burn Gel / After Burn Spray / Alphacaine / Anestacon Jelly / DermaFlex / Dilocaine / Esracaine / L-Caine / Lidoject-1 / Lidoject-2 / LidoPain SP / Norwood Sunburn Spray / Xylocard
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
0.4% Lidocaine Hydrochloride and 5% Dextrose Injection USPLidocaine hydrochloride (4 mg) + Glucose (50 mg)SolutionIntravenousHospira, Inc.1983-12-31Not applicableCanada
10 Person ANSILidocaine + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Ibuprofen + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-24Not applicableUs
1st RELIEF TOPICALLidocaine (40 mg/mL) + Menthol (10 mg/mL)SprayTopical1st Class Pharmaceuticals2014-12-02Not applicableUs
2% Lidocaine and Epinephrine 1:100,000 Injection USPLidocaine hydrochloride (20 mg) + Epinephrine (0.01 mg)LiquidInfiltrationAlveda Pharmaceuticals Inc2008-12-01Not applicableCanada
25 Person ANSILidocaine + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Ibuprofen + Isopropyl Alcohol + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-25Not applicableUs
3-Step First Aid KitLidocaine hydrochloride + Benzalkonium chloride + Povidone-iodineKitTopicalSwabplus Inc.2003-03-01Not applicableUs
5% Xylocaine Mpf With Glucose 7.5% InjectionLidocaine hydrochloride (5 %) + Glucose (7.5 %)LiquidSubarachnoidSmiths Medical Canada Ltd.Not applicableNot applicableCanada
50 Person ANSILidocaine + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Ibuprofen + Isopropyl Alcohol + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-06-02Not applicableUs
ACME FIRST AID Contains 404 PIECESLidocaine + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Isopropyl Alcohol + Neomycin sulfate + Polymyxin B Sulfate + WaterKitAcme United Corporation2010-04-27Not applicableUs
ACME Small Cuts and BurnsLidocaine + Bacitracin zinc + Benzalkonium chloride + Neomycin sulfate + Polymyxin B SulfateKitAcme United Corporation2010-04-30Not applicableUs
Categories
UNII
98PI200987
CAS number
137-58-6
Weight
Average: 234.3373
Monoisotopic: 234.173213336
Chemical Formula
C14H22N2O
InChI Key
NNJVILVZKWQKPM-UHFFFAOYSA-N
InChI
InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)
IUPAC Name
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide
SMILES
CCN(CC)CC(=O)NC1=C(C)C=CC=C1C

Pharmacology

Indication

For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.

Structured Indications
Pharmacodynamics

Lidocaine is an anesthetic agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Lidocaine appears to be similar to that of procaine, procainamide and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. In contrast to the latter 3 drugs, Lidocaine in therapeutic doses does not produce a significant decrease in arterial pressure or in cardiac contractile force. In larger doses, lidocaine may produce circulatory depression, but the magnitude of the change is less than that found with comparable doses of procainamide.

Mechanism of action

Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na+) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anaesthetic effect by not merely preventing pain signals from propagating to the brain but by aborting their birth in the first place.

TargetActionsOrganism
ASodium channel protein type 10 subunit alpha
inhibitor
Human
ASodium channel protein type 9 subunit alpha
inhibitor
Human
ASodium channel protein type 5 subunit alpha
inhibitor
Human
UEpidermal growth factor receptor
antagonist
Human
USodium channel protein type 4 subunit alphaNot AvailableHuman
UAlpha-1-acid glycoprotein 1Not AvailableHuman
UAlpha-1-acid glycoprotein 2Not AvailableHuman
Absorption

Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent.

Volume of distribution
  • 0.7 to 2.7 L/kg [healthy volunteers]
Protein binding

60-80%

Metabolism

Primarily hepatic.

Route of elimination

Lidocaine and its metabolites are excreted by the kidneys.

Half life

109 minutes

Clearance
  • 0.64 +/- 0.18 L/min
Toxicity

The oral LD 50 of lidocaine HCl in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Lidocaine (Local Anaesthetic) Action PathwayDrug action
Lidocaine (Antiarrhythmic) Action PathwayDrug action
Lidocaine (Local Anaesthetic) Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Lidocaine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Lidocaine can be increased when it is combined with Abiraterone.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Lidocaine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Lidocaine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Lidocaine.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Lidocaine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Lidocaine.Approved
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Lidocaine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Lidocaine is combined with Alaproclate.Experimental
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Lidocaine.Approved, Vet Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Lidocaine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Lidocaine.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Lidocaine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Allopregnanolone.Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Lidocaine.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Lidocaine.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Lidocaine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lidocaine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Lidocaine can be increased when it is combined with Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Lidocaine.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Lidocaine.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Lidocaine.Approved
AmiodaroneThe serum concentration of Lidocaine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Lidocaine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lidocaine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Amperozide.Experimental
AnagrelideThe metabolism of Anagrelide can be decreased when combined with Lidocaine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Lidocaine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Lidocaine.Approved
AprepitantThe serum concentration of Lidocaine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lidocaine.Approved, Investigational
ArotinololThe serum concentration of Lidocaine can be increased when it is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Lidocaine.Approved, Investigational
ArtemetherThe metabolism of Lidocaine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Articaine.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Lidocaine.Approved
AtazanavirThe metabolism of Lidocaine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Lidocaine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Lidocaine is combined with Atorvastatin.Approved
AV650The metabolism of AV650 can be decreased when combined with Lidocaine.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Lidocaine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Azaperone.Vet Approved
AzelastineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Lidocaine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Lidocaine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Lidocaine is combined with Barbital.Illicit
BefunololThe serum concentration of Lidocaine can be increased when it is combined with Befunolol.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Lidocaine.Approved, Investigational
BendamustineThe metabolism of Bendamustine can be decreased when combined with Lidocaine.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Lidocaine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Benzocaine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Lidocaine.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Lidocaine.Approved, Vet Approved
BetaxololThe serum concentration of Lidocaine can be increased when it is combined with Betaxolol.Approved
BevantololThe serum concentration of Lidocaine can be increased when it is combined with Bevantolol.Approved
BisoprololThe serum concentration of Lidocaine can be increased when it is combined with Bisoprolol.Approved
BoceprevirThe metabolism of Lidocaine can be decreased when combined with Boceprevir.Withdrawn
BopindololThe serum concentration of Lidocaine can be increased when it is combined with Bopindolol.Approved
BortezomibThe metabolism of Lidocaine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Lidocaine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Lidocaine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lidocaine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Lidocaine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Lidocaine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Lidocaine is combined with Bromisoval.Experimental
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Lidocaine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Lidocaine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Lidocaine is combined with Brotizolam.Approved, Withdrawn
BucindololThe serum concentration of Lidocaine can be increased when it is combined with Bucindolol.Investigational
BufuralolThe serum concentration of Lidocaine can be increased when it is combined with Bufuralol.Experimental, Investigational
BunaftineLidocaine may increase the arrhythmogenic activities of Bunaftine.Experimental
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Lidocaine.Approved, Investigational
BupranololThe serum concentration of Lidocaine can be increased when it is combined with Bupranolol.Approved
BuprenorphineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Lidocaine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Lidocaine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lidocaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Lidocaine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Lidocaine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Lidocaine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lidocaine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Lidocaine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lidocaine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Lidocaine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Lidocaine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Lidocaine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Lidocaine is combined with Canertinib.Investigational
CapecitabineThe metabolism of Lidocaine can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Lidocaine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Lidocaine is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Lidocaine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Lidocaine is combined with Carisoprodol.Approved
CarmustineThe metabolism of Carmustine can be decreased when combined with Lidocaine.Approved
CarteololThe serum concentration of Lidocaine can be increased when it is combined with Carteolol.Approved
CarvedilolThe serum concentration of Lidocaine can be increased when it is combined with Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Lidocaine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Lidocaine can be increased when it is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Lidocaine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Lidocaine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Lidocaine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lidocaine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Lidocaine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Chlorphenamine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Lidocaine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Lidocaine.Approved
CholecalciferolThe metabolism of Lidocaine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe metabolism of Cilostazol can be decreased when combined with Lidocaine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Lidocaine.Approved
CinacalcetThe metabolism of Lidocaine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Lidocaine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Lidocaine.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Lidocaine.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Lidocaine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Lidocaine.Approved
ClarithromycinThe metabolism of Lidocaine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Lidocaine can be decreased when combined with Clemastine.Approved
ClenbuterolThe metabolism of Clenbuterol can be decreased when combined with Lidocaine.Approved, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Lidocaine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Lidocaine is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Lidocaine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Lidocaine is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Lidocaine.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Lidocaine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Lidocaine is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Lidocaine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Lidocaine is combined with Clopenthixol.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Lidocaine.Approved, Nutraceutical
CloranololThe serum concentration of Lidocaine can be increased when it is combined with Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lidocaine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Lidocaine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Lidocaine.Approved
CobicistatThe serum concentration of Lidocaine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Lidocaine.Approved
CocaineThe metabolism of Lidocaine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Lidocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Lidocaine.Approved
ConivaptanThe serum concentration of Lidocaine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Lidocaine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Lidocaine.Approved
CrisaboroleThe metabolism of Lidocaine can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Lidocaine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Lidocaine.Approved
CyclosporineThe metabolism of Lidocaine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Lidocaine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lidocaine.Approved
DabrafenibThe serum concentration of Lidocaine can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Lidocaine.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Lidocaine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Lidocaine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dapoxetine.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Lidocaine.Approved, Investigational
DarifenacinThe metabolism of Lidocaine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Lidocaine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Lidocaine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Lidocaine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Lidocaine.Approved
DeferasiroxThe serum concentration of Lidocaine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Lidocaine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lidocaine.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Lidocaine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Detomidine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Lidocaine.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Lidocaine.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dexbrompheniramine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Lidocaine.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Lidocaine.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Lidocaine.Approved, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Lidocaine is combined with Diethyl ether.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lidocaine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Lidocaine is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Lidocaine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lidocaine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lidocaine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lidocaine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lidocaine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Lidocaine.Experimental
DihydroergotamineThe metabolism of Lidocaine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Lidocaine.Illicit
DiltiazemThe metabolism of Lidocaine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dimenhydrinate.Approved
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Lidocaine.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Lidocaine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lidocaine.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Lidocaine.Approved
DisopyramideDisopyramide may increase the arrhythmogenic activities of Lidocaine.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dixyrazine.Experimental
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Lidocaine.Approved, Investigational
DofetilideLidocaine may increase the arrhythmogenic activities of Dofetilide.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Lidocaine.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Lidocaine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Lidocaine can be decreased when combined with Dosulepin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Lidocaine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Lidocaine.Approved, Investigational
DoxycyclineThe metabolism of Lidocaine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Lidocaine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Illicit
DronedaroneLidocaine may increase the arrhythmogenic activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Lidocaine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Lidocaine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Lidocaine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Lidocaine is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Lidocaine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Lidocaine.Approved, Investigational
EliglustatThe metabolism of Lidocaine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Eltanolone.Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Lidocaine.Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Lidocaine.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Lidocaine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Lidocaine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Lidocaine can be decreased when it is combined with Enzalutamide.Approved
EpanololThe serum concentration of Lidocaine can be increased when it is combined with Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Lidocaine.Approved, Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lidocaine.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Lidocaine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Lidocaine.Approved, Investigational
ErythromycinThe metabolism of Lidocaine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Lidocaine is combined with Escitalopram.Approved, Investigational
EsmololThe serum concentration of Lidocaine can be increased when it is combined with Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Lidocaine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Lidocaine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Lidocaine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Lidocaine.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Lidocaine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lidocaine.Approved
EthanolLidocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lidocaine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lidocaine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Lidocaine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Lidocaine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Lidocaine.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Lidocaine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Lidocaine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Lidocaine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Lidocaine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Lidocaine is combined with Felbamate.Approved
FelodipineThe metabolism of Lidocaine can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lidocaine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lidocaine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Lidocaine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Lidocaine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Lidocaine is combined with Flibanserin.Approved
FloxuridineThe metabolism of Lidocaine can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Lidocaine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Lidocaine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Lidocaine.Approved, Illicit
FluorouracilThe metabolism of Lidocaine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Lidocaine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lidocaine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lidocaine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lidocaine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluspirilene.Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Lidocaine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Lidocaine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Lidocaine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Lidocaine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Lidocaine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lidocaine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Lidocaine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Lidocaine.Approved, Investigational
Fusidic AcidThe serum concentration of Lidocaine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lidocaine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Lidocaine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lidocaine.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Lidocaine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Lidocaine.Approved
GemfibrozilThe metabolism of Lidocaine can be decreased when combined with Gemfibrozil.Approved
GenisteinThe metabolism of Genistein can be decreased when combined with Lidocaine.Investigational
GepironeThe risk or severity of adverse effects can be increased when Lidocaine is combined with Gepirone.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Lidocaine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Glutethimide.Approved, Illicit
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Lidocaine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Lidocaine.Withdrawn
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Lidocaine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Lidocaine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Lidocaine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Lidocaine is combined with Heroin.Approved, Illicit
HesperetinThe metabolism of Hesperetin can be decreased when combined with Lidocaine.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Lidocaine.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Lidocaine.Approved, Investigational
HydrocodoneLidocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Lidocaine.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lidocaine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Lidocaine.Approved
IbutilideLidocaine may increase the arrhythmogenic activities of Ibutilide.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Lidocaine.Approved, Investigational
IdelalisibThe serum concentration of Lidocaine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Lidocaine.Approved
ImatinibThe metabolism of Lidocaine can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Lidocaine.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Lidocaine.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Lidocaine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Indalpine.Investigational, Withdrawn
IndenololThe serum concentration of Lidocaine can be increased when it is combined with Indenolol.Withdrawn
IndinavirThe metabolism of Lidocaine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Lidocaine is combined with Indiplon.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Lidocaine.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lidocaine.Approved
IrbesartanThe metabolism of Lidocaine can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Lidocaine.Approved, Investigational
IsavuconazoniumThe metabolism of Lidocaine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lidocaine.Approved, Vet Approved
IsoniazidThe metabolism of Lidocaine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Lidocaine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Lidocaine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Lidocaine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Lidocaine.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Lidocaine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lidocaine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Lidocaine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Lidocaine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe serum concentration of Lidocaine can be increased when it is combined with Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Lidocaine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Lidocaine.Approved, Investigational
LandiololThe serum concentration of Lidocaine can be increased when it is combined with Landiolol.Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Lidocaine.Approved, Investigational
LapatinibThe metabolism of Lidocaine can be decreased when combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Lidocaine.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Lidocaine.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Lidocaine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Lidocaine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Lidocaine.Approved, Investigational
LevobunololThe serum concentration of Lidocaine can be increased when it is combined with Levobunolol.Approved
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Lidocaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Lidocaine is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Lidocaine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Lidocaine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Lidocaine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lidocaine.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Lidocaine.Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Lidocaine.Approved
LithiumThe risk or severity of adverse effects can be increased when Lidocaine is combined with Lithium.Approved
LobeglitazoneThe metabolism of Lidocaine can be decreased when combined with Lobeglitazone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lidocaine is combined with Lofentanil.Illicit
LomefloxacinThe metabolism of Lomefloxacin can be decreased when combined with Lidocaine.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Lidocaine.Approved
LopinavirThe metabolism of Lidocaine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Lidocaine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lidocaine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Lidocaine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lidocaine is combined with Lormetazepam.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Lidocaine.Approved
LovastatinThe metabolism of Lidocaine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Lidocaine.Approved
LuliconazoleThe serum concentration of Lidocaine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Lidocaine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lidocaine can be decreased when combined with Lumefantrine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Lidocaine.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lidocaine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Lidocaine.Illicit, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
MalathionThe metabolism of Malathion can be decreased when combined with Lidocaine.Approved, Investigational
ManidipineThe metabolism of Lidocaine can be decreased when combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Lidocaine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Lidocaine.Approved
MebicarThe risk or severity of adverse effects can be increased when Lidocaine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Lidocaine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Medetomidine.Vet Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Lidocaine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Melperone.Approved
MenadioneThe metabolism of Menadione can be decreased when combined with Lidocaine.Approved, Nutraceutical
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Lidocaine.Investigational, Withdrawn
MepindololThe serum concentration of Lidocaine can be increased when it is combined with Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lidocaine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Lidocaine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Lidocaine.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Lidocaine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Lidocaine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Lidocaine.Approved
MethotrimeprazineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Lidocaine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methylecgonine.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Lidocaine.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Lidocaine.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Lidocaine.Approved
MetipranololThe serum concentration of Lidocaine can be increased when it is combined with Metipranolol.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Lidocaine.Approved, Investigational
MetyrosineLidocaine may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Lidocaine.Experimental
MexiletineThe metabolism of Lidocaine can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Lidocaine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Lidocaine.Approved, Illicit
MidostaurinThe metabolism of Lidocaine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Lidocaine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Lidocaine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Lidocaine.Approved
MirtazapineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Lidocaine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Lidocaine.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Lidocaine.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Lidocaine.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lidocaine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Investigational
NabumetoneThe metabolism of Nabumetone can be decreased when combined with Lidocaine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lidocaine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Lidocaine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Lidocaine.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Lidocaine.Approved, Vet Approved
NefazodoneThe metabolism of Lidocaine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Lidocaine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Lidocaine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Lidocaine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Lidocaine can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Lidocaine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Lidocaine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Lidocaine.Approved
NilotinibThe metabolism of Lidocaine can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Lidocaine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lidocaine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Lidocaine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lidocaine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Lidocaine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Lidocaine.Approved
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Lidocaine.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Lidocaine.Approved, Investigational
OlaparibThe metabolism of Lidocaine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Lidocaine.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Lidocaine.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Lidocaine.Approved
OpiumThe risk or severity of adverse effects can be increased when Lidocaine is combined with Opium.Approved, Illicit
OrphenadrineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Lidocaine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Lidocaine can be increased when it is combined with Osimertinib.Approved
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Lidocaine.Approved, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lidocaine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Oxethazaine.Investigational
OxprenololThe serum concentration of Lidocaine can be increased when it is combined with Oxprenolol.Approved
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Lidocaine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lidocaine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lidocaine.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Lidocaine.Approved, Vet Approved
PalbociclibThe serum concentration of Lidocaine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lidocaine.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Lidocaine.Approved, Investigational
PanobinostatThe serum concentration of Lidocaine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Lidocaine.Approved
ParaldehydeLidocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Lidocaine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Lidocaine.Approved
Peginterferon alfa-2bThe serum concentration of Lidocaine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe serum concentration of Lidocaine can be increased when it is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Lidocaine is combined with Penfluridol.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Lidocaine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lidocaine.Approved, Vet Approved
PentobarbitalThe metabolism of Lidocaine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Lidocaine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Perazine.Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Lidocaine.Approved, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Lidocaine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Lidocaine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lidocaine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Lidocaine.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Lidocaine is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Lidocaine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Lidocaine is combined with Phenoxyethanol.Approved
PhenytoinThe metabolism of Lidocaine can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Lidocaine.Approved
PimozideThe metabolism of Pimozide can be decreased when combined with Lidocaine.Approved
PindololThe serum concentration of Lidocaine can be increased when it is combined with Pindolol.Approved
PioglitazoneThe metabolism of Lidocaine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Pipamperone.Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Lidocaine.Approved
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Lidocaine.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Lidocaine.Approved
PizotifenThe risk or severity of adverse effects can be increased when Lidocaine is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Lidocaine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Lidocaine.Approved
PosaconazoleThe metabolism of Lidocaine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Lidocaine can be increased when it is combined with Practolol.Approved
PramipexoleLidocaine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Lidocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Lidocaine is combined with Prazepam.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Lidocaine.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Lidocaine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Lidocaine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Lidocaine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lidocaine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Prilocaine.Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Lidocaine.Approved
PrimidoneThe metabolism of Lidocaine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lidocaine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Lidocaine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Lidocaine.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Lidocaine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Promethazine.Approved
PropafenoneThe metabolism of Propafenone can be decreased when combined with Lidocaine.Approved
PropanididThe risk or severity of adverse effects can be increased when Lidocaine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Proparacaine.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Lidocaine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Lidocaine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Lidocaine.Approved
PSD502The risk or severity of adverse effects can be increased when Lidocaine is combined with PSD502.Investigational
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Lidocaine.Approved
PyrimethamineThe metabolism of Lidocaine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Lidocaine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Lidocaine.Approved
QuinidineThe metabolism of Lidocaine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Lidocaine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Quinisocaine.Experimental
RabeprazoleThe metabolism of Lidocaine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Raclopride.Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Lidocaine.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Lidocaine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Lidocaine.Approved, Investigational
RasagilineThe metabolism of Rasagiline can be decreased when combined with Lidocaine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lidocaine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Lidocaine.Approved
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Lidocaine.Experimental, Investigational
RifabutinThe metabolism of Lidocaine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Lidocaine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Lidocaine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Lidocaine.Approved, Investigational
RiluzoleThe metabolism of Riluzole can be decreased when combined with Lidocaine.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Lidocaine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Lidocaine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Lidocaine.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Lidocaine.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Lidocaine.Investigational, Withdrawn
RolapitantThe metabolism of Lidocaine can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Lidocaine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Romifidine.Vet Approved
RopiniroleLidocaine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Lidocaine.Approved
RosiglitazoneThe metabolism of Lidocaine can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Lidocaine.Approved
RotigotineLidocaine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Lidocaine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Lidocaine.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Lidocaine.Approved, Vet Approved
SaquinavirSaquinavir may increase the arrhythmogenic activities of Lidocaine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Lidocaine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Lidocaine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Lidocaine.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Lidocaine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lidocaine.Approved, Vet Approved
SildenafilThe metabolism of Lidocaine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Lidocaine.Approved
SiltuximabThe serum concentration of Lidocaine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Lidocaine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Lidocaine.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Lidocaine.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Lidocaine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Lidocaine.Approved, Investigational
SotalolThe serum concentration of Lidocaine can be increased when it is combined with Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Lidocaine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Lidocaine.Experimental
St. John's WortThe serum concentration of Lidocaine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Lidocaine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lidocaine.Approved, Investigational
SulfadiazineThe metabolism of Lidocaine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Lidocaine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Lidocaine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sultopride.Experimental
SuvorexantLidocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe metabolism of Tacrine can be decreased when combined with Lidocaine.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Lidocaine.Approved, Investigational
TalinololThe serum concentration of Lidocaine can be increased when it is combined with Talinolol.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Lidocaine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Lidocaine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Lidocaine.Approved
Technetium Tc-99m tilmanoceptLidocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved
TedisamilLidocaine may increase the arrhythmogenic activities of Tedisamil.Investigational
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Lidocaine.Withdrawn
TelithromycinThe metabolism of Lidocaine can be decreased when combined with Telithromycin.Approved
TemafloxacinThe metabolism of Temafloxacin can be decreased when combined with Lidocaine.Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Lidocaine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Lidocaine.Approved
Tenofovir disoproxilThe metabolism of Lidocaine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Lidocaine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Lidocaine.Experimental
TeriflunomideThe serum concentration of Lidocaine can be decreased when it is combined with Teriflunomide.Approved
TertatololThe serum concentration of Lidocaine can be increased when it is combined with Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tetrodotoxin.Investigational
ThalidomideLidocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be decreased when combined with Lidocaine.Approved
TheophyllineThe metabolism of Lidocaine can be decreased when combined with Theophylline.Approved
ThiabendazoleThe metabolism of Thiabendazole can be decreased when combined with Lidocaine.Approved, Vet Approved
ThiamylalThe risk or severity of adverse effects can be increased when Lidocaine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Lidocaine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Lidocaine.Withdrawn
ThiotepaThe metabolism of Lidocaine can be decreased when combined with Thiotepa.Approved
ThiothixeneThe metabolism of Thiothixene can be decreased when combined with Lidocaine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Lidocaine.Approved
TiclopidineThe metabolism of Lidocaine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tilidine.Experimental
TipranavirThe metabolism of Lidocaine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Lidocaine.Approved
TocilizumabThe serum concentration of Lidocaine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Lidocaine can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Lidocaine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Lidocaine is combined with Topiramate.Approved
TopiroxostatThe metabolism of Lidocaine can be decreased when combined with Topiroxostat.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Lidocaine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Lidocaine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Lidocaine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Lidocaine can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Lidocaine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Trazodone.Approved, Investigational
TriamtereneThe metabolism of Triamterene can be decreased when combined with Lidocaine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Lidocaine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Lidocaine is combined with Trichloroethylene.Experimental
TrifluoperazineThe metabolism of Trifluoperazine can be decreased when combined with Lidocaine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Lidocaine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe metabolism of Lidocaine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Triprolidine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Lidocaine.Experimental
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Lidocaine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Lidocaine.Approved
VadimezanThe metabolism of Vadimezan can be decreased when combined with Lidocaine.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Lidocaine is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Lidocaine can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Lidocaine.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Lidocaine.Approved
VemurafenibThe serum concentration of Lidocaine can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Lidocaine.Approved
VenlafaxineThe metabolism of Lidocaine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Veralipride.Experimental
VerapamilThe metabolism of Lidocaine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Lidocaine is combined with Vigabatrin.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Lidocaine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Lidocaine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Lidocaine is combined with Vinyl ether.Experimental
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Lidocaine.Approved
VoriconazoleThe metabolism of Lidocaine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Vortioxetine.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Lidocaine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Lidocaine.Approved
XenonThe risk or severity of adverse effects can be increased when Lidocaine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Lidocaine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lidocaine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Lidocaine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Lidocaine.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Lidocaine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Lidocaine is combined with Zolazepam.Vet Approved
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Lidocaine.Approved, Investigational
ZolpidemLidocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Lidocaine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Lidocaine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Zotepine.Approved
ZucapsaicinThe metabolism of Lidocaine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lidocaine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US2441498A
General References
  1. Khaliq W, Alam S, Puri N: Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004846. [PubMed:17443559]
  2. Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M: Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med. 1973 Apr;78(4):499-508. [PubMed:4694036]
  3. Geha PY, Baliki MN, Chialvo DR, Harden RN, Paice JA, Apkarian AV: Brain activity for spontaneous pain of postherpetic neuralgia and its modulation by lidocaine patch therapy. Pain. 2007 Mar;128(1-2):88-100. Epub 2006 Oct 25. [PubMed:17067740]
  4. Hines R, Keaney D, Moskowitz MH, Prakken S: Use of lidocaine patch 5% for chronic low back pain: a report of four cases. Pain Med. 2002 Dec;3(4):361-5. [PubMed:15099246]
External Links
Human Metabolome Database
HMDB14426
KEGG Drug
D00358
KEGG Compound
C07073
PubChem Compound
3676
PubChem Substance
46505060
ChemSpider
3548
BindingDB
50017662
ChEBI
6456
ChEMBL
CHEMBL79
Therapeutic Targets Database
DAP000121
PharmGKB
PA450226
IUPHAR
2623
Guide to Pharmacology
GtP Drug Page
HET
LQZ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lidocaine
ATC Codes
C01BB01 — LidocaineD04AB01 — LidocaineN01BB02 — LidocaineS02DA01 — LidocaineR02AD02 — LidocaineC05AD01 — LidocaineS01HA07 — LidocaineN01BB52 — Lidocaine, combinations
AHFS Codes
  • 84:08.00 — Antipruritics and Local Anesthetics
  • 24:04.00 — Cardiac Drugs
  • 24:04.04.08 — Class Ib Antiarrythmics
  • 72:00.00 — Local Anesthetics
  • 52:16.00 — Local Anesthetics
PDB Entries
3jqz / 3ttr
FDA label
Download (548 KB)
MSDS
Download (74.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceMorton's neuralgia1
0CompletedHealth Services ResearchPain1
0CompletedSupportive CareCutaneous Abscess / Pain1
0CompletedTreatmentTinnitus1
0Not Yet RecruitingPreventionColorectal Cancers1
0Not Yet RecruitingSupportive CareBariatric Surgery Candidate1
0Not Yet RecruitingTreatmentNeoplasms, Lung / Pleural Effusion, Malignant1
0RecruitingOtherHeat Effect1
0RecruitingTreatmentChorionic Villi Sampling1
1Active Not RecruitingNot AvailableAAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Fibrosis, Liver1
1Active Not RecruitingOtherSurgery, Colorectal1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceDrug-induced QT Interval Prolongation / Pharmacodynamics / Pharmacokinetics1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceNociceptive Pain / Peripheral Neuropathic Pain1
1CompletedHealth Services ResearchAnaesthesia therapy1
1CompletedPreventionIntradermal Electroporation1
1CompletedPreventionOther Preterm Infants1
1CompletedSupportive CareEtomidate Overdose of Undetermined Intent1
1CompletedTreatment"Lost" IUD / Lost IUD1
1CompletedTreatmentCoughing1
1CompletedTreatmentFibromyalgia / Pain, Chronic1
1CompletedTreatmentHyperalgesia / Pain1
1CompletedTreatmentIpsilateral Shoulder Pain1
1CompletedTreatmentNeoplasms, Cystic, Mucinous, and Serous1
1CompletedTreatmentPain Management / Pregnancy Termination1
1CompletedTreatmentProvoked Vestibulodynia / Provoked, Localized Vulvodynia / Vulvar Vestibulitis / Vulvodynia1
1Not Yet RecruitingSupportive CareLocal Anesthesia / Neoplasms, Brain1
1Not Yet RecruitingTreatmentPostoperative pain1
1Not Yet RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
1RecruitingTreatmentIntermetatarsal Neuroma1
1RecruitingTreatmentPompe's Disease1
1RecruitingTreatmentRadicular syndrome / Sciatica1
1TerminatedTreatmentAcute-onset Herpes Zoster Pain1
1TerminatedTreatmentPain, Neuropathic1
1, 2CompletedPreventionHemodynamic Changes Due to Propofol Injection / Pain Due to Propofol Injection1
1, 2CompletedSupportive CareAnalgesia1
1, 2CompletedTreatmentOsteoarthritis of the Knees1
1, 2RecruitingPreventionBariatric Surgery Candidate / BMI >30 kg/m21
1, 2RecruitingPreventionChemotherapy-induced Peripheral Neuropathy (CIPN) / Colorectal Cancers / Neuropathy, Painful1
1, 2TerminatedPreventionPain1
1, 2Unknown StatusTreatmentAnaesthesia therapy1
1, 2WithdrawnTreatmentColorectal Disorders1
1, 2WithdrawnTreatmentInjuries and Wounds1
1, 2WithdrawnTreatmentPostoperative Pain Management After Total Hip Arthroplasty1
2CompletedBasic ScienceDiabetic Neuropathic Pain1
2CompletedPreventionDysmenorrhea1
2CompletedPreventionHyperalgesia / Knee Joint Osteoarthrosis / Severe Movement Related Pain1
2CompletedPreventionRotator Cuff Syndrome1
2CompletedSupportive CareDental Anesthesia Efficacy1
2CompletedSupportive CareDiverticulitis / Inflammatory Bowel Diseases (IBD) / Malignant Neoplasm of Colon1
2CompletedSupportive CareMucositis1
2CompletedSupportive CareOral Mucositis1
2CompletedSupportive CareSupratentorial Craniotomy Dysfunction1
2CompletedTreatmentAllodynia / Central Neuropathic Pain / Spinal Cord Injuries (SCI)1
2CompletedTreatmentAnesthetics, Local / Pain / Venipuncture1
2CompletedTreatmentCarpal Tunnel Syndrome (CTS)1
2CompletedTreatmentChronic Low Back Pain (CLBP)1
2CompletedTreatmentChronic Pain Syndrome / Prostatitis1
2CompletedTreatmentDysmenorrhea / Endometriosis1
2CompletedTreatmentFascicular Block / Latency Period / Motor Activities / Postoperative pain1
2CompletedTreatmentFeeling Anxious / Pain1
2CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentHemorrhoids1
2CompletedTreatmentHip Pain Etiology Unknown1
2CompletedTreatmentIrritable Bowel Syndrome (IBS)1
2CompletedTreatmentLocal Anesthesia1
2CompletedTreatmentLow Back Pain (LBP)1
2CompletedTreatmentMyofascial Pain Syndromes1
2CompletedTreatmentObesity, Morbid / Postoperative pain1
2CompletedTreatmentOsteoarthritis of the Knees2
2CompletedTreatmentPain3
2CompletedTreatmentPain, Neuropathic / Vasoocclusive Sickle Cell Crises Pains1
2CompletedTreatmentPatellar Tendinopathy1
2CompletedTreatmentPostherpetic Neuralgia2
2CompletedTreatmentPostoperative pain1
2CompletedTreatmentShoulder Impingement Syndrome1
2CompletedTreatmentShoulder Pain / Strokes1
2CompletedTreatmentUrinary Tract Infections (UTIs)1
2CompletedTreatmentVulvodynia1
2Enrolling by InvitationPreventionNormal Pulp/ Pulpitis1
2Not Yet RecruitingPreventionIntubations / Stellate Ganglion1
2Not Yet RecruitingTreatmentAllodynic Symptoms / Localized Neuropathic Pain1
2Not Yet RecruitingTreatmentAnesthetics, Local1
2Not Yet RecruitingTreatmentUrethral Strictures1
2RecruitingPreventionIntraoperative Bleeding1
2RecruitingPreventionPostoperative paralytic ileus1
2RecruitingSupportive CareCancer, Breast1
2RecruitingTreatmentAnaesthesia therapy / Local Infiltration1
2RecruitingTreatmentBladder Pain Syndrome / Interstitial Cystitis1
2RecruitingTreatmentDependence, Cocaine1
2RecruitingTreatmentDiabetic Polyneuropathy / Peripheral Neuropathy / Postherpetic Neuralgia1
2RecruitingTreatmentElective Cesarean Delivery / Valve Heart Disease1
2RecruitingTreatmentInterstitial Cystitis / Painful Bladder Syndrome (PBS)1
2RecruitingTreatmentLeiomyomas1
2RecruitingTreatmentPain1
2RecruitingTreatmentPhantom Limb Pain (PLP) / Primary/Secondary Scar Hyperalgesia1
2TerminatedTreatmentDry Macular Degeneration1
2TerminatedTreatmentPruritus1
2TerminatedTreatmentVulvar Vestibulitis1
2Unknown StatusPreventionCancer, Breast1
2Unknown StatusTreatmentShoulder Pain2
2WithdrawnTreatmentCerebrovascular Accidents / Strokes1
2WithdrawnTreatmentNeoplasms / Pain1
2WithdrawnTreatmentPain1
2, 3CompletedPreventionPain Relief During Prostate Biopsy1
2, 3CompletedTreatmentCardiac Catheterizations / Spasms1
2, 3CompletedTreatmentHerpes Zoster Pain1
2, 3CompletedTreatmentInterferential Current Drug Delivery1
2, 3CompletedTreatmentInterstitial Lung Disease (ILD) / Lung Cancers / Sarcoidosis / Tuberculosis1
2, 3CompletedTreatmentPain and Anxiety1
2, 3CompletedTreatmentPain / Surgical Abortion1
2, 3CompletedTreatmentPostcesarean Pain Relief1
2, 3CompletedTreatmentPostoperative pain1
2, 3Not Yet RecruitingPreventionDiscomfort / Pain1
2, 3Not Yet RecruitingTreatmentCarpal Tunnel Syndrome (CTS)1
2, 3Not Yet RecruitingTreatmentPain, Acute1
2, 3RecruitingPreventionImproving Quality of Life1
2, 3RecruitingSupportive CareCancer-related Pain1
2, 3RecruitingTreatmentPain1
2, 3TerminatedTreatmentElective Surgical Procedure / Surgery, Colorectal1
2, 3Unknown StatusPreventionWe Focus on the Pain of Venipuncture and Intravenous Cannulation1
2, 3Unknown StatusTreatmentAchilles Tendinopathy / Achilles Tendon Enthesopathy / Insertional Achilles Tendinopathy / Mid-Portion Achilles Tendinopathy / Non-Insertional Achilles Tendinopathy1
2, 3Unknown StatusTreatmentHemorrhoids1
3Active Not RecruitingPreventionChronic Post-surgical Pain / Post-mastectomy Pain Syndrome1
3CompletedNot AvailableLocal Anesthesia1
3CompletedBasic ScienceBMI >30 kg/m2 / Post-gastrointestinal bypass surgery1
3CompletedDiagnosticGynecologic Diseases1
3CompletedPreventionElective Major Abdominal Surgery1
3CompletedPreventionRadiation Dermatitis1
3CompletedSupportive CareAnalgesia1
3CompletedSupportive CarePain / Tiredness1
3CompletedSupportive CarePain / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedSupportive CareProcedural Pain Relief1
3CompletedSupportive CareSubtenon Anesthesia1
3CompletedTreatmentAbdominal Pain (AP) / Gastroesophageal Reflux Disease / Indigestion / Intestinal Malabsorption1
3CompletedTreatmentAnaesthesia therapy2
3CompletedTreatmentAnkle Sprains1
3CompletedTreatmentBiceps Tendonitis1
3CompletedTreatmentCardiac Arrest1
3CompletedTreatmentChronic Low Back Pain (CLBP)1
3CompletedTreatmentDiabetes Mellitus (DM)1
3CompletedTreatmentFacial Wrinkles at the Nasolabial Folds1
3CompletedTreatmentForearm and Arm Surgery1
3CompletedTreatmentInguinal Pain1
3CompletedTreatmentIrreversible Pulpitis1
3CompletedTreatmentMastectomy1
3CompletedTreatmentModerate or Severe Submental Fullness1
3CompletedTreatmentNeoplasms, Colorectal1
3CompletedTreatmentNonviable Pregnancy1
3CompletedTreatmentPain11
3CompletedTreatmentPain Management, Cervical Preparation1
3CompletedTreatmentPain Teeth1
3CompletedTreatmentPharyngitis1
3CompletedTreatmentPostoperative pain4
3CompletedTreatmentProcedural Pain1
3CompletedTreatmentSpinal Anaesthesia1
3CompletedTreatmentPostoperative paralytic ileus1
3Not Yet RecruitingPreventionAdjunct to general anesthesia therapy / Anaesthesia therapy / Analgesics / Analgesics, Opioid / Dexmedetomidine / Gabapentin / Ketamine / Lidocaine / Narcotics / Obstructive Sleep Apnea of Child / Oximetry, Pulse / Pathologic Processes / Physiologic Effects of Drugs / Postoperative Complications / Respiratory Depression / Sleep Disordered Breathing (SDB) / Tonsillectomy1
3Not Yet RecruitingTreatmentBariatric Surgery Candidate / Obesity, Morbid1
3Not Yet RecruitingTreatmentContraception1
3Not Yet RecruitingTreatmentPain, Chronic1
3RecruitingDiagnosticNeurocostal neuralgia / Peripheral Neuropathic Pain1
3RecruitingDiagnosticPostoperative pain1
3RecruitingSupportive CarePain1
3RecruitingTreatmentCancers / Pain With Neuropathic Component1
3RecruitingTreatmentCarcinologic Ear, Nose, and Throat (ENT) Surgery1
3RecruitingTreatmentContraception / Lidocaine1
3RecruitingTreatmentInguinal Hernias / Local Anesthesia / Sedation, Conscious1
3RecruitingTreatmentLow Back Pain (LBP) / Modic I Discopathy1
3RecruitingTreatmentPain, Chronic1
3RecruitingTreatmentPelvic Pain1
3RecruitingTreatmentPostoperative pain1
3RecruitingTreatmentStrokes1
3RecruitingTreatmentUterine Hemorrhage1
3TerminatedPreventionTransient Neurologic Syndrome1
3TerminatedTreatmentAnalgesia, Postoperative / Opioid Free Anaesthesia1
3TerminatedTreatmentBone Marrow Diseases / Pain1
3TerminatedTreatmentBursitis / Periarthritis1
3TerminatedTreatmentCarpal Tunnel Syndrome (CTS)1
3Unknown StatusNot AvailableInduction of Total Intravenous General Anesthesia1
3Unknown StatusPreventionBariatric Surgical Pain1
3Unknown StatusTreatmentCancers / Pain1
3Unknown StatusTreatmentFibromyalgia1
3Unknown StatusTreatmentHealthy Volunteers1
3Unknown StatusTreatmentPeripheral Neuropathy1
3Unknown StatusTreatmentUndernutrition1
3WithdrawnTreatmentParathyroid Diseases1
4Active Not RecruitingTreatmentCarpal Tunnel Syndrome (CTS)1
4Active Not RecruitingTreatmentLocal Anesthesia1
4Active Not RecruitingTreatmentPain1
4Active Not RecruitingTreatmentPostoperative pain1
4CompletedNot AvailableAnaesthesia therapy1
4CompletedNot AvailableAnaesthesia / Caudal epidural block therapy / Orthopaedic Disorders1
4CompletedNot AvailableNeuromuscular Block1
4CompletedNot AvailablePain of Anesthesia at Breast Biopsy1
4CompletedNot AvailablePeriodontal Diseases1
4CompletedNot AvailableUterine Leiomyomas1
4CompletedBasic ScienceLow Back Pain (LBP)1
4CompletedOtherPain1
4CompletedPreventionAnesthesia of Mucous Membrane1
4CompletedPreventionCardiovascular Morbidity / Intubation Complications1
4CompletedPreventionChildbirth / Parturients1
4CompletedPreventionEsophagogastroduodenoscopy1
4CompletedPreventionGeneral Surgery / Pain1
4CompletedPreventionLaminectomy1
4CompletedPreventionNeonatal Infections1
4CompletedPreventionOpioid Consumption, Postoperative / Postoperative Fatigue / Postoperative pain1
4CompletedPreventionPain2
4CompletedPreventionPain on Injection of Propofol,Lidocaine, Alkalinized Lidocaine1
4CompletedPreventionPost-Operative Pain1
4CompletedPreventionPostoperative pain3
4CompletedPreventionThroat Pain1
4CompletedScreeningPostoperative pain1
4CompletedSupportive CareArterial Catheterization1
4CompletedSupportive CareCervical Pain / Pelvic Pain1
4CompletedSupportive CareCognitive Function Abnormal / Intraoperative Monitoring / Vitreoretinal Surgery1
4CompletedSupportive CareElectrodiagnosis1
4CompletedSupportive CareIntravenous Anesthetic Interaction "Unrecognized Condition" / Intravenous Anesthetic Interaction Unrecognized Condition1
4CompletedSupportive CareLeukemias / Non Hodgkin Lymphoma (NHL)1
4CompletedSupportive CarePain5
4CompletedSupportive CarePain, Neuropathic / Postmastectomy Pain1
4CompletedSupportive CareQuality of Ocular Akinesia (Onset and Duration)1
4CompletedSupportive CareSedation, Conscious1
4CompletedTreatmentAcute and Chronic Non-radicular LBP1
4CompletedTreatmentAdhesive Capsulitis1
4CompletedTreatmentAdverse Effects1
4CompletedTreatmentAnalgesic Requirement / Inadequate or Impaired Respiratory Function / Postoperative pain / Return of Bowel Activity / Stress Response1
4CompletedTreatmentBack Pain / Cervical Pain1
4CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
4CompletedTreatmentBimalleolar Fractures of the Ankle / Post Operative Analgesia Duration / Saphenous Nerve Block / Sciatic Nerve Block1
4CompletedTreatmentBlock Level / Gastrointestinal Surgery / Target Controlled Infusion (TCI) / Thoracic Epidural Anesthesia1
4CompletedTreatmentCanal Syndrome / Pudendal Neuralgia1
4CompletedTreatmentCarpal Tunnel Syndrome (CTS) / Complex Regional Pain Syndrome (CRPS) / Diabetic Neuropathies / HIV Neuropathy / Idiopathic Sensory Neuropathy / Peripheral Neuropathy / Postherpetic Neuralgia1
4CompletedTreatmentCarpal Tunnel Syndrome (CTS) / Trigger Finger1
4CompletedTreatmentChronic Calculous Cholecystitis1
4CompletedTreatmentChronic Cough (CC)1
4CompletedTreatmentChronic Low Back Pain (CLBP)1
4CompletedTreatmentChronic Periodontitis / Diabetes Mellitus (DM)1
4CompletedTreatmentComplication of Injection / Pain1
4CompletedTreatmentConscious Sedation Failure During Procedure1
4CompletedTreatmentDermatitis Papillaris Capillitii / Tattooing1
4CompletedTreatmentDiabetes1
4CompletedTreatmentDiabetic Neuropathies / Low Back Pain (LBP) / Postherpetic Neuralgia1
4CompletedTreatmentDisseminated Sclerosis1
4CompletedTreatmentEpicondylitis of the Elbow1
4CompletedTreatmentEpicondylitis, Lateral Humeral / Lateral Epicondylitis1
4CompletedTreatmentFeeling Anxious / Nausea / Pain1
4CompletedTreatmentFissure;Anal / Fistula;Rectal / Hemorrhoids1
4CompletedTreatmentGall Stone Disease1
4CompletedTreatmentHallux Valgus1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHeart Diseases1
4CompletedTreatmentIUD Insertion1
4CompletedTreatmentIV Insertion Pain1
4CompletedTreatmentInjection Site Irritation1
4CompletedTreatmentAdjunct to general anesthesia therapy / Intravenous Anesthesia1
4CompletedTreatmentIntravenous Injections1
4CompletedTreatmentIrreversible Pulpitis1
4CompletedTreatmentIrreversible Pulpitis / Pain1
4CompletedTreatmentKnee Arthroplasty, Total1
4CompletedTreatmentLocal Anesthesia for Peripheral Intravenous Catheterization / Pain1
4CompletedTreatmentLocal Anesthesia of the Skin2
4CompletedTreatmentLow Back Pain (LBP) / Spinal Stenosis1
4CompletedTreatmentLung Cancers1
4CompletedTreatmentMigrainous Headache1
4CompletedTreatmentMyofascial Pain Syndrome / Myofascial Trigger Point Pain / Pain / Painful musculoskeletal conditions1
4CompletedTreatmentNeuromuscular Block1
4CompletedTreatmentNose Deformities, Acquired1
4CompletedTreatmentOpen Reduction Internal Fixation(ORIF) of Lateral Malleolus1
4CompletedTreatmentNeurocostal neuralgia / Opioid-Related Disorders1
4CompletedTreatmentOsteoarthritis of the Knees1
4CompletedTreatmentPain5
4CompletedTreatmentPain Associated With Epidural Needle Insertion1
4CompletedTreatmentPain on IV Injection of Propofol1
4CompletedTreatmentPain, Acute1
4CompletedTreatmentPain, Chronic1
4CompletedTreatmentPain, Neuropathic1
4CompletedTreatmentPain / Prophylaxis against postoperative nausea and vomiting1
4CompletedTreatmentOr Peripheral Nerve Injury (PNI) / Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)1
4CompletedTreatmentPersistent Post-menpausal Bleeding / Uterine Cancers / Uterine Leiomyomas1
4CompletedTreatmentPostoperative Sore Throat, Cough, Hoarseness1
4CompletedTreatmentPostoperative pain1
4CompletedTreatmentPostoperative pain / Postoperative paralytic ileus / Prophylaxis against postoperative nausea and vomiting1
4CompletedTreatmentAdjunct to general anesthesia therapy / Propofol Target-controlled Infusion / Thoracic Epidural Anesthesia1
4CompletedTreatmentSedation, Conscious1
4CompletedTreatmentSpinal Anaesthesia1
4CompletedTreatmentThermal Burns1
4CompletedTreatmentTinnitus1
4CompletedTreatmentTopical Anesthesia1
4CompletedTreatmentGallstone formation1
4Enrolling by InvitationTreatmentAnesthesia Complication / Hemodynamics Instability / Ileus paralytic / Nausea / Postoperative pain / Vomiting1
4Enrolling by InvitationTreatmentLocal Anesthesia1
4Enrolling by InvitationTreatmentPain1
4Not Yet RecruitingBasic ScienceHealthy Volunteers1
4Not Yet RecruitingPreventionCritical Illness1
4Not Yet RecruitingPreventionNeurocostal neuralgia / Pain, Acute / Pain, Chronic1
4Not Yet RecruitingPreventionThroat Pain1
4Not Yet RecruitingPreventionUrinary Catheter Discomfort in Surgical Patients1
4Not Yet RecruitingTreatmentAbdominal Pain (AP)1
4Not Yet RecruitingTreatmentCervical Radiculitis / Pain1
4Not Yet RecruitingTreatmentLaparoscopic Colon Resection / Perioperative analgesia1
4Not Yet RecruitingTreatmentLocal Anesthesia / Spinal Diseases1
4Not Yet RecruitingTreatmentLow Back Pain (LBP)1
4Not Yet RecruitingTreatmentSpinal Diseases1
4RecruitingNot AvailablePain1
4RecruitingDiagnosticFemale Infertility of Tubal Origin1
4RecruitingPreventionAnginal Pain / Coronary Artery Disease / Radial Artery Spasm1
4RecruitingSupportive CareAnaesthesia therapy1
4RecruitingSupportive CareAnesthesia, Intravenous; Surgery, Plastic1
4RecruitingSupportive CareColon Diverticulosis / Colonic Neoplasms / Constipation Drug Induced / Diverticulitis, Colonic / Ileus / Ileus paralytic / Ileus; Mechanical / Malignant Neoplasm of Colon / Occasional Constipation / Postoperative pain / Rectum Cancer / Rectum Neoplasm1
4RecruitingSupportive CareColonoscopy1
4RecruitingSupportive CareNerve Monitoring / Thyroidectomy1
4RecruitingTreatmentAcute Low Back Pain1
4RecruitingTreatmentAnalgesia / Urolithiasis1
4RecruitingTreatmentArrhythmias Ventricular1
4RecruitingTreatmentCerebrospinal Fluid Leaks / Postdural Puncture Headache / Spinal; Puncture, Complications, Headache1
4RecruitingTreatmentCicatrix1
4RecruitingTreatmentCoronary Artery Disease1
4RecruitingTreatmentInjections, Spinal / Morphine / Patients Satisfaction / Prostatectomy1
4RecruitingTreatmentLateral Epicondylitis1
4RecruitingTreatmentMigraines1
4RecruitingTreatmentMyofascial Pain Syndrome1
4RecruitingTreatmentOpioids Use1
4RecruitingTreatmentPain, Radiating1
4RecruitingTreatmentPost Operative Pain1
4RecruitingTreatmentPostoperative Pain Management1
4RecruitingTreatmentPostoperative pain1
4RecruitingTreatmentSedation therapy1
4RecruitingTreatmentShoulder Pain1
4RecruitingTreatmentTolerance1
4RecruitingTreatmentCaudal epidural block therapy / Transurethral Resection / Urinary Bladder Neoplasms1
4RecruitingTreatmentPost-pancreatectomy1
4SuspendedNot AvailableOnset and Duration of a Digital Nerve Block1
4SuspendedBasic SciencePain1
4SuspendedSupportive CareLocal Anesthesia / Wounds1
4TerminatedDiagnosticPain1
4TerminatedPreventionNausea / Occasional Constipation / Pain / Vomiting1
4TerminatedPreventionPain1
4TerminatedSupportive CarePain1
4TerminatedTreatmentAbscesses1
4TerminatedTreatmentArthritis Multiple Joint / Basal Thumb Joint Arthritis / Basilar Joint Arthritis / Carpometacarpal Arthritis / Trapeziometacarpal Arthritis1
4TerminatedTreatmentChronic Low Back Pain (CLBP)1
4TerminatedTreatmentDisseminated Sclerosis / Pain, Chronic / Pain, Neuropathic1
4TerminatedTreatmentFace Pain1
4TerminatedTreatmentForearm Fractures1
4TerminatedTreatmentNasolabial Folds1
4TerminatedTreatmentOsteoarthritis of the Knees1
4TerminatedTreatmentPelvic Pain1
4TerminatedTreatmentPulmonary Arterial Hypertension (PAH)1
4TerminatedTreatmentTrigger Finger Disorder1
4Unknown StatusNot AvailableDependence, Cocaine1
4Unknown StatusNot AvailableEndophthalmitis / Vitreoretinal Surgery1
4Unknown StatusBasic ScienceColorectal Cancers1
4Unknown StatusDiagnosticHealthy Volunteers1
4Unknown StatusPreventionDrug Usage1
4Unknown StatusPreventionGynecological Pathologies1
4Unknown StatusPreventionOral Hemorrhage1
4Unknown StatusSupportive CareInjection Site Irritation1
4Unknown StatusTreatmentAnaesthesia therapy / Analgesia / Conscious Sedation Failure During Procedure1
4Unknown StatusTreatmentCholecystolithiasis1
4Unknown StatusTreatmentDilatation and Evacuation / Laminaria Placement / Pain Alleviation1
4Unknown StatusTreatmentFractures of the Distal Radius1
4Unknown StatusTreatmentIUD Insertion Complication / Pain Control1
4Unknown StatusTreatmentInfraclavicular Brachial Plexus Block1
4Unknown StatusTreatmentPlanned Abdominal Hysterectomy1
4Unknown StatusTreatmentPostoperative Agitation of Patients1
4Unknown StatusTreatmentPostoperative pain4
4Unknown StatusTreatmentRetinal Detachment1
4Unknown StatusTreatmentSternotomy1
4Unknown StatusTreatmentAdjunct to general anesthesia therapy1
4WithdrawnNot AvailableAdjunct to general anesthesia therapy / Elderly / Surgeries Requiring A Minimum One Day Hospitalization1
4WithdrawnNot AvailableFeeling Anxious / Pain1
4WithdrawnTreatmentAbdominal Cutaneous Nerve Entrapment Syndrome / Chronic Abdominal Wall Pain1
4WithdrawnTreatmentBursitis1
4WithdrawnTreatmentCataract Surgery Anesthesia1
Not AvailableActive Not RecruitingSupportive CareBreastcancer / Phyllodes Breast Tumor1
Not AvailableActive Not RecruitingTreatmentAnaesthesia therapy2
Not AvailableActive Not RecruitingTreatmentBMI >30 kg/m21
Not AvailableActive Not RecruitingTreatmentLow Back Pain (LBP) / Osteoarthritis Nos, of Sacroiliac Joint / Sprain of Sacroiliac Ligament1
Not AvailableActive Not RecruitingTreatmentNeedle Insertion and Injection Pain1
Not AvailableActive Not RecruitingTreatmentPost-Operative Pain1
Not AvailableActive Not RecruitingTreatmentRotator Cuff / Subacromial Impingement Syndrome1
Not AvailableActive Not RecruitingTreatmentHair removal therapy1
Not AvailableCompletedNot AvailableAnaesthesia therapy1
Not AvailableCompletedNot AvailableArrythmias / Blood Electrolyte Balance / Coronary Artery Bypass Graft / Dexmedetomidine / Lidocaine / Myocardial Injury / Unstable Angina (UA)1
Not AvailableCompletedNot AvailableCancer, Breast1
Not AvailableCompletedNot AvailableEpilepsies1
Not AvailableCompletedNot AvailableFemoroacetabular Impingement1
Not AvailableCompletedNot AvailableHemodynamic Response1
Not AvailableCompletedNot AvailableMethaemoglobinaemia1
Not AvailableCompletedNot AvailablePain2
Not AvailableCompletedNot AvailablePain, Neuropathic2
Not AvailableCompletedNot AvailableRhytidoplasty1
Not AvailableCompletedNot AvailableThyroid Cancers1
Not AvailableCompletedNot AvailableTrigger Finger1
Not AvailableCompletedBasic ScienceDepressive State1
Not AvailableCompletedBasic ScienceDiabetic Foot Proned Patients1
Not AvailableCompletedBasic ScienceUrethral Analgesia1
Not AvailableCompletedDiagnosticBronchopulmonary Diseases2
Not AvailableCompletedDiagnosticConscious Sedation Failure During Procedure1
Not AvailableCompletedDiagnosticPain1
Not AvailableCompletedHealth Services ResearchObesity, Morbid1
Not AvailableCompletedOtherOsteoarthritis of the Knees1
Not AvailableCompletedPreventionAdult Disease1
Not AvailableCompletedPreventionAnaesthesia therapy / Coughing / Extubation1
Not AvailableCompletedPreventionBMI >30 kg/m2 / Pain1
Not AvailableCompletedPreventionCognitive Decline1
Not AvailableCompletedPreventionGeneral Surgery1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV)1
Not AvailableCompletedPreventionIntrauterine Device / Pain1
Not AvailableCompletedPreventionMyoma of Uterus1
Not AvailableCompletedPreventionNeoplasm, Gastric1
Not AvailableCompletedPreventionOther Intraoperative Cardiac Functional Disturbances During Cardiac Surgery1
Not AvailableCompletedPreventionPain3
Not AvailableCompletedPreventionPancreatitis1
Not AvailableCompletedPreventionPharyngitis1
Not AvailableCompletedPreventionPostoperative pain1
Not AvailableCompletedPreventionThyroidectomy1
Not AvailableCompletedSupportive CareCataracts1
Not AvailableCompletedSupportive CareColorectal Cancers1
Not AvailableCompletedSupportive CareInfertilities1
Not AvailableCompletedSupportive CareInflammatory Reaction / Postoperative pain1
Not AvailableCompletedSupportive CareLabour Pain1
Not AvailableCompletedSupportive CarePain6
Not AvailableCompletedSupportive CareParkinson's Disease (PD)1
Not AvailableCompletedSupportive CareTrigeminal Neuralgia (TN)1
Not AvailableCompletedSupportive CareSynovitis of osteoarthritis1
Not AvailableCompletedTreatmentAge-Related Macular Degeneration (AMD)1
Not AvailableCompletedTreatmentAge-Related Macular Degeneration (ARMD) / Central Retinal Vein Occlusion (CRVO) / Diabetic Macular Edema (DME)1
Not AvailableCompletedTreatmentAllergic Skin Reaction / Anxiety Disorders1
Not AvailableCompletedTreatmentAnesthetics, Local / Blood Levels of Buffered vs Non-buffered Lidocaine1
Not AvailableCompletedTreatmentBirth Injuries / Laceration / Pain1
Not AvailableCompletedTreatmentCarpal Tunnel Syndrome (CTS)1
Not AvailableCompletedTreatmentContraception / Pain1
Not AvailableCompletedTreatmentDiverticulitis / Inflammatory Bowel Diseases (IBD) / Malignant Neoplasm of Colon1
Not AvailableCompletedTreatmentDrug Usage1
Not AvailableCompletedTreatmentElective Total or Subtotal Abdominal Hysterectomy1
Not AvailableCompletedTreatmentEndometriosis1
Not AvailableCompletedTreatmentFibromyalgia1
Not AvailableCompletedTreatmentFracture Bone / Pain1
Not AvailableCompletedTreatmentJellyfish Stings1
Not AvailableCompletedTreatmentLaparoscopic Cholecystectomy1
Not AvailableCompletedTreatmentLateral Epicondylitis1
Not AvailableCompletedTreatmentLocal Anesthesia / Postoperative pain / Self-Perception1
Not AvailableCompletedTreatmentLow Back Pain (LBP)1
Not AvailableCompletedTreatmentLumbar Puncture / Topical Analgesia1
Not AvailableCompletedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedTreatmentMigraines1
Not AvailableCompletedTreatmentMigrainous Headache1
Not AvailableCompletedTreatmentNeed for Urethral Catheterization to Rule Out Urinary Tract Infection / Pediatric Presentation of Urinary Tract Infection1
Not AvailableCompletedTreatmentOpioid Consumption / Postoperative pain1
Not AvailableCompletedTreatmentPain12
Not AvailableCompletedTreatmentPain Control for Intrauterine Device Insertions1
Not AvailableCompletedTreatmentPain Intensity1
Not AvailableCompletedTreatmentPartial Thickness Rotator Cuff Tear / Subacromial Impingement Syndrome1
Not AvailableCompletedTreatmentPedal Fat Pad Atrophy1
Not AvailableCompletedTreatmentPelvic Floor Disorders1
Not AvailableCompletedTreatmentPerioperative Chest Pain1
Not AvailableCompletedTreatmentPlantar fascial fibromatosis1
Not AvailableCompletedTreatmentPost Operative Pain1
Not AvailableCompletedTreatmentPostoperative pain3
Not AvailableCompletedTreatmentPregnancy Termination / Uterine Curettage1
Not AvailableCompletedTreatmentProstate Cancer1
Not AvailableCompletedTreatmentRenal Stones1
Not AvailableCompletedTreatmentRotator Cuff Disease1
Not AvailableCompletedTreatmentSacroiliitis1
Not AvailableCompletedTreatmentSpine Surgery1
Not AvailableCompletedTreatmentStrokes1
Not AvailableCompletedTreatmentVestibulodynia1
Not AvailableCompletedTreatmentMinor burns1
Not AvailableEnrolling by InvitationNot AvailableArthritis / Gout Acute / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1
Not AvailableEnrolling by InvitationNot AvailableBrain Diseases / Cardiovascular Disease (CVD) / Central Nervous System Diseases / Cerebrovascular Disorders / Cerebrovascular Stroke / Ischemia, Brain / Nervous System Diseases / Strokes / Vascular Diseases1
Not AvailableNot Yet RecruitingBasic ScienceChronic Low Back Pain (CLBP)1
Not AvailableNot Yet RecruitingPreventionAnaesthesia therapy / Spinal Puncture1
Not AvailableNot Yet RecruitingPreventionGallbladder disorders1
Not AvailableNot Yet RecruitingPreventionHemodynamics Instability1
Not AvailableNot Yet RecruitingTreatmentAnalgesia / IUD Insertion1
Not AvailableNot Yet RecruitingTreatmentBrachial Plexus Block / Shoulder Dislocation1
Not AvailableNot Yet RecruitingTreatmentCancer, Breast / Mastectomy / Post Operative Pain / Regional Anesthesia1
Not AvailableNot Yet RecruitingTreatmentKnee Arthroplasty, Total / Radiologic Tibiofemoral Osteoarthritis / Synovitis of osteoarthritis1
Not AvailableNot Yet RecruitingTreatmentPain2
Not AvailableNot Yet RecruitingTreatmentPain Management / Peripheral Nerve Blocks / Sedation therapy / Total Knee Arthroplasty (TKA)1
Not AvailableRecruitingNot AvailablePain1
Not AvailableRecruitingBasic SciencePain1
Not AvailableRecruitingDiagnosticDysuria / Hematuria / Recurrent Uti1
Not AvailableRecruitingDiagnosticNeuroma / Pain, Neuropathic1
Not AvailableRecruitingOtherAnesthesia; Reaction1
Not AvailableRecruitingOtherCircumcision / Postoperative pain / Regional Anesthesia1
Not AvailableRecruitingPreventionAgitation States as Acute Reaction to Gross Stress1
Not AvailableRecruitingPreventionArterial Hypotension1
Not AvailableRecruitingPreventionContraception1
Not AvailableRecruitingPreventionMetal Staple Removal After Total Knee Replacement1
Not AvailableRecruitingPreventionNonvalvular Atrial Fibrillation1
Not AvailableRecruitingPreventionNulliparity1
Not AvailableRecruitingPreventionPostoperative pain1
Not AvailableRecruitingSupportive CareAbdominal Cancer1
Not AvailableRecruitingSupportive CareInvasive Bladder Cancer1
Not AvailableRecruitingSupportive CareKidney Failure,Chronic1
Not AvailableRecruitingSupportive CareLumbar Radiculopathy Due to Spinal Nerve Compression1
Not AvailableRecruitingSupportive CarePain1
Not AvailableRecruitingSupportive CareSynovitis of osteoarthritis1
Not AvailableRecruitingTreatmentAbdominal Pain (AP) / GERD / Swallowing Disorders1
Not AvailableRecruitingTreatmentAdductor Canal Block / Anaesthesia therapy1
Not AvailableRecruitingTreatmentAnaesthesia therapy / Surgery--Complications1
Not AvailableRecruitingTreatmentArthritis / Back Pain1
Not AvailableRecruitingTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentBiceps Tendonitis / Injections1
Not AvailableRecruitingTreatmentCarpal Tunnel Syndrome (CTS)1
Not AvailableRecruitingTreatmentDiabetes / Pain / Peripheral Neuropathy1
Not AvailableRecruitingTreatmentHeart Failure, Unspecified2
Not AvailableRecruitingTreatmentHeel Fat Pad Atrophy1
Not AvailableRecruitingTreatmentIUD Insertion Complication1
Not AvailableRecruitingTreatmentInterstitial Cystitis / Painful Bladder Syndrome (PBS)1
Not AvailableRecruitingTreatmentPain1
Not AvailableRecruitingTreatmentPelvic Organ Prolapse (POP)1
Not AvailableRecruitingTreatmentPeripheral Solitary Pulmonary Nodule or Tuberculoma1
Not AvailableRecruitingTreatmentPilonidal Sinus1
Not AvailableRecruitingTreatmentThe Comparison of the I-gel and Endotracheal Tube About in Different Ventilation Settings During Laparoscopic Surgery1
Not AvailableSuspendedSupportive CareNeoplasms, Malignant1
Not AvailableSuspendedTreatmentPaediatric Flexible Bronchoscopy1
Not AvailableTerminatedBasic SciencePain1
Not AvailableTerminatedDiagnosticLabour Pain1
Not AvailableTerminatedPreventionGeneral Surgery / Pain / Pregnancy1
Not AvailableTerminatedPreventionIntubation; Difficult1
Not AvailableTerminatedPreventionLaryngospasm1
Not AvailableTerminatedTreatmentHysterectomy1
Not AvailableTerminatedTreatmentLaparoscopic Colorectal Resection1
Not AvailableTerminatedTreatmentLumbar Puncture / Meningitis / Pain1
Not AvailableTerminatedTreatmentLumbar and Other Intervertebral Disc Disorders With Radiculopathy1
Not AvailableTerminatedTreatmentMigraines1
Not AvailableTerminatedTreatmentNausea / Pain1
Not AvailableTerminatedTreatmentPain2
Not AvailableUnknown StatusNot AvailableCesarean Delivery / Pain1
Not AvailableUnknown StatusNot AvailablePlantar Warts1
Not AvailableUnknown StatusNot AvailableType 2 Diabetes Mellitus1
Not AvailableUnknown StatusBasic ScienceAnesthetics, Local1
Not AvailableUnknown StatusEducational/Counseling/TrainingPain1
Not AvailableUnknown StatusPreventionAsymptomatic Gallstones Without Cholecystitis / Gallbladder Polyps1
Not AvailableUnknown StatusPreventionContraception1
Not AvailableUnknown StatusPreventionThroat Pain1
Not AvailableUnknown StatusSupportive CareOverweight and Obesity1
Not AvailableUnknown StatusTreatmentInfertilities1
Not AvailableUnknown StatusTreatmentMacular Degeneration1
Not AvailableUnknown StatusTreatmentPain2
Not AvailableUnknown StatusTreatmentPain During and After Endovenous Laser Obliteration of Large Saphenous Vein Based on Lidocaine Tumescent Concentration1
Not AvailableUnknown StatusTreatmentPregnancy1
Not AvailableUnknown StatusTreatmentRenal Stones / Ureteral Calculus1
Not AvailableUnknown StatusTreatmentTuberculosis1
Not AvailableUnknown StatusTreatmentType 2 Diabetes Mellitus1
Not AvailableWithdrawnNot AvailableAirway Complication of Anaesthesia1
Not AvailableWithdrawnNot AvailablePain1
Not AvailableWithdrawnDiagnosticInterstitial Cystitis1
Not AvailableWithdrawnPreventionGeneral Surgery / Pain1
Not AvailableWithdrawnPreventionSpinal Puncture Complications1
Not AvailableWithdrawnSupportive CarePain1
Not AvailableWithdrawnTreatmentAdhesive Capsulitis1
Not AvailableWithdrawnTreatmentBack Pain1
Not AvailableWithdrawnTreatmentLabour / Pregnant1
Not AvailableWithdrawnTreatmentNasolabial Folds Correction / Pain1
Not AvailableWithdrawnTreatmentPain1
Not AvailableWithdrawnTreatmentPlantar fascial fibromatosis1
Not AvailableWithdrawnTreatmentTotal Knee Arthroplasty (TKA)1

Pharmacoeconomics

Manufacturers
  • Astrazeneca lp
  • Noven pharmaceuticals inc
  • Carlisle laboratories inc
  • E fougera div altana inc
  • Graham chemical co
  • Taro pharmaceuticals usa inc
  • Teikoku pharma usa inc
  • Abbott laboratories pharmaceutical products div
  • Abbott laboratories hosp products div
  • Abraxis pharmaceutical products
  • Akorn inc
  • Baxter healthcare corp anesthesia and critical care
  • Bel mar laboratories inc
  • Dell laboratories inc
  • Elkins sinn div ah robins co inc
  • Gd searle llc
  • Hospira inc
  • International medication systems ltd
  • International medication system
  • Luitpold pharmaceuticals inc
  • Miles laboratories inc
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Baxter healthcare corp
  • B braun medical inc
  • App pharmaceuticals llc
  • Meridian medical technologies inc
  • Dentsply pharmaceutical
  • Polymedica industries inc
  • Teva pharmaceuticals usa
  • Hi tech pharmacal co inc
  • Wockhardt eu operations (swiss) ag
  • Actavis mid atlantic llc
  • Vintage pharmaceuticals llc
  • Roxane laboratories inc
  • Kendall co
  • Paco research corp
  • Anesiva inc
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous20 mg
LiquidSubarachnoid
PatchTopical246 mg/1
Kit
KitOral; Topical
GelTopical25 mg/mL
SolutionTopical1 %
Liquid; sprayTopical0.5 %
GelTopical0.5 %
GelTopical2.5 g/100g
KitTopical
GelOphthalmic35 mg/mL
GelTopical5 mg/mL
GelTopical4 %
OintmentTopical4 g/100mL
SwabTopical4 g/100mL
GelTopical.5 g/100mL
GelTopical.5 g/100g
GelTopical2.5 g/g
LiquidInfiltration; Subcutaneous1 %
CreamTopical5 g/100mL
LiquidEpidural1 %
OintmentTopical.05 g/g
Kit; liquidIntravenous
LiquidIntravenous
LiquidIntra-articular1 %
OintmentTopical246 mg/1
LotionTopical4 g/100g
CreamTopical2 g/100g
ImplantIntradermal.3 %
GelTopical4.1 mg/mL
GelTopical0.7 %
LiquidTopical2 %
CreamTopical2 %
GelTopical2 g/100g
CreamTopical2.8 g/56g
Aerosol, sprayTopical
CreamTopical40 mg/1
SprayTopical10 mg/mg
SprayTopical20 mg/L
CreamTopical2.25 %
GelTopical2 g/100mL
GelTopical2.5 g/100mL
SprayTopical2 g/100mL
GelTopical0.72 %
SprayTopical.05 g/100g
SprayTopical.5 g/100g
SprayTopical200 g/L
SprayTopical2.4 %
GelTopical5.05 g/g
GelTopical.025 g/g
CreamTopical.04 mg/mg
GelTopical1.0 %
GelTopical20 mg
TabletDental
Liquid; ointmentIntravenous; Topical
Kit; liquid; ointmentInfiltration; Parenteral; Subcutaneous; Topical
LiquidEpidural; Infiltration; Subcutaneous
PatchTopical560 mg/1
CreamTopical4 g/100mL
CreamTopical40 mg/mL
GelTopical5 mg/g
RinseTopical
SolutionIntra-articular; Intrabursal
SprayTopical50 mg/g
CreamTopical38.8 mg/g
KitTopical
CreamTopical1.5 g/30g
CreamTopical5 g/100g
SprayTopical10 mg/.08mL
Kit
LotionTopical4 g/mL
SprayTopical10 mg/100mL
Kit; ointment; solutionInfiltration; Intravenous; Topical
CreamTopical20 mg/1000mg
SprayTopical40 mg/1000mg
CreamTopical40 mg/1000mg
GelTopical40 mg/1000mg
LiquidTopical40 mg/1000mg
CreamTopical4 mg/mL
Liquid; sprayTopical
SwabTopical
SprayTopical
SprayCutaneous
GelTopical10 mg/g
SprayTopical10 mg/mL
GelTopical2 %
KitIntra-amniotic
AerosolTopical40 mg/g
GelTopical500 g/100000mg
SprayCutaneous.5 g/100g
OintmentTopical4 g/100g
CreamTopical5.0 %
GelTopical.8 g/100g
GelTopical0.8 %
CreamTopical45 mg/mL
LiquidTopical
SoapTopical
SprayTopical40 mg/g
Injection, solutionIntra-articular
Liquid; ointmentEpidural; Topical
LotionTopical.5 g/100mL
GelTopical4 g/50g
LotionTopical
Spray, meteredTopical96 mg/mL
LiquidEndotracheal40 mg
SolutionTopical40 mg/mL
Aerosol, sprayTopical.64 g/127g
Injection, solutionInfiltration10 mg/mL
OintmentTopical10 1/1
OintmentTopical2.5 g/50g
OintmentTopical35.44 g/g
OintmentTopical5 g/100g
OintmentTopical50 mg/g
PatchCutaneous140 mg/1
PatchCutaneous700 mg/1
SolutionInfiltration
Injection, solutionInfiltration20 mg/mL
CreamRectal; Topical
SolutionIntravenous
LiquidEpidural; Infiltration10 mg
LiquidInfiltration10 mg
LiquidIntravenous20 mg
CreamTopical30 mg/g
GelTopical20 mg/g
GelTopical30 mg/g
GelTopical40 mg/g
InjectionEpidural; Infiltration; Intracaudal10 mg/mL
InjectionInfiltration; Intravenous10 mg/mL
InjectionInfiltration; Intravenous20 mg/mL
InjectionInfiltration; Intravenous5 mg/mL
InjectionIntravenous20 mg/mL
InjectionParenteral20 mg/mL
Injection, solutionEpidural; Infiltration10 mg/mL
Injection, solutionEpidural; Infiltration20 mg/mL
Injection, solutionEpidural; Infiltration; Intracaudal10 mg/mL
Injection, solutionEpidural; Infiltration; Intracaudal20 mg/mL
Injection, solutionEpidural; Infiltration; Intracaudal; Perineural10 mg/mL
Injection, solutionEpidural; Infiltration; Intracaudal; Perineural20 mg/mL
Injection, solutionEpidural; Infiltration; Perineural20 mg/mL
Injection, solutionInfiltration; Intravenous5 mg/mL
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous20 mg/mL
Injection, solutionRetrobulbar; Topical40 mg/mL
JellyTopical20 mg/mL
LiquidTopical20 mg/mL
LiquidTopical200 mL/L
LotionTopical3 g/100mL
LotionTopical5.31 mL/177mL
SolutionOral20 mg/mL
SolutionOropharyngeal20 mg/mL
SolutionTopical20 mg/mL
SprayTopical20 g/L
SolutionEpidural; Infiltration
Injection, solutionIntravenous
Injection, solutionIntravenous4 mg/mL
Injection, solutionIntravenous400 mg/100mL
Injection, solutionIntravenous8 mg/mL
Injection, solutionIntravenous800 mg/100mL
Injection, solutionDental; Infiltration
Injection, solutionEpidural
Injection, solutionInfiltration
CreamRectal
GelRectal
SolutionInfiltration5 mg
LiquidInfiltration2 %
SolutionInfiltration20 mg
SolutionInfiltration10 mg
SprayTopical1 %
GelOral2 g/100mL
SolutionInfiltration1 %
SolutionInfiltration2 %
OintmentTopical5 g
CreamTopical39.2 mg/mL
SolutionOral; Topical20 mg/mL
PatchTopical4 g/1
PatchTopical11 mg/1
SprayTopical20 mg/mL
GelTopical7.2 g/240g
SprayTopical4.6 g/115g
CreamTopical10 g/100g
SolutionTopical4 %
LiquidTopical10 mg
JellyTopical20 mg
JellyTopical2 %
OintmentTopical5 %
LiquidBuccal2 %
PatchCutaneous700 mg/12h
LiquidCutaneous700 mg/1000mg
PatchTopical22.7 mg/.24mg
PatchTopical25.3 mg/.24mg
PatchTopical25.8 mg/.24mg
PatchTopical28.1 mg/.24mg
PatchTopical29 mg/.24mg
PatchTopical21.5 mg/.24mg
LiquidAuricular (otic)
PatchTopical
PatchTransdermal
CreamTopical32.5 mg/g
CreamTopical37.5 mg/g
CreamTopical39.5 mg/g
KitOral
SprayTopical10 mg/.1mL
LiquidInfiltration
CreamTopical40 mg/g
CreamTopical50 mg/g
LiquidSubcutaneous1 %
Spray, meteredTopical9.6 mg/100mL
CreamTopical4 %
CreamTopical5 %
PatchTopical40 mg/1
AerosolTopical
GelTopical.04 g/g
GelTopical10 mg/mL
Solution / dropsOphthalmic; Topical
Liquid; ointmentSubcutaneous; Topical
LiquidInfiltration; Intraspinal; Subcutaneous1 %
SolutionIntramuscular; Intravenous
CreamTopical50 mg/mL
Spray, meteredTopical
SprayTopical24.64 mg/mL
CreamTopical5 mg/g
CreamTopical5 mg/30g
SprayTopical.04 mg/mg
SolutionTopical
StickTopical
LiquidDental; Subcutaneous
Injection, solutionSubcutaneous
LiquidSubcutaneous
GelPeriodontal
SuspensionAuricular (otic)
CreamTopical.04 g/40g
LotionTopical40 mg/4mL
LiquidTopical4 g/100mL
CreamTopical4 g/100g
PatchTopical.3 g/1
GelTopical7.13 mg/mL
LiquidInfiltration; Subcutaneous; Topical
GelTopical2 mg/g
LiquidIntravenous1 %
Kit; ointment; solutionInfiltration; Subcutaneous; Topical
CreamTopical41.2 mg/g
KitInfiltration; Intra-articular; Intramuscular; Respiratory (inhalation); Topical
LiquidEpidural; Intravenous
CreamTopical
LiquidDental2 %
Solution / dropsAuricular (otic)
SprayTopical2.6 %
SprayTopical4 %
SolutionTopical40 mg
CreamTopical400 mg/mg
OintmentTopical.005 mg/g
Spray, meteredTopical9.6 g/100mL
OintmentTopical10 mg/mL
SprayTopical10 g/100g
PackingDental
KitEpidural; Infiltration; Intramuscular; Intravenous
KitEpidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue
KitEpidural; Infiltration
KitEpidural; Infiltration; Intra-articular; Intramuscular; Topical
CreamTopical.04 g/g
CreamTopical.05 g/g
ClothTopical
GelTopical1 g/100g
GelTopical20 mg/mL
LiquidTopical40 mg/mL
GelTopical4 g/100g
SprayTopical2 %
SolutionTopical2 %
PatchPercutaneous; Topical; Transdermal560 mg/1
CreamPercutaneous; Topical; Transdermal
LiquidPercutaneous; Topical; Transdermal
SprayTopical1.1 g/12g
GelTopical2.0 %
GelTopical40 mg/mL
GelTopical1 %
SprayTopical5 mg/g
LotionTopical0.5 %
SprayTopical4 g/100mL
GelTopical.057 mg/mL
GelTopical0.50 %
CreamTopical.5 g/100g
KitInfiltration; Topical
LiquidParenteral; Topical
LiquidInfiltration; Subcutaneous
KitInfiltration1 %
SprayTopical96 mg/mL
Spray, meteredTopical9.6 %
AerosolTopical0.5 %
SwabTopical1 %
PatchCutaneous
OintmentTopical
PatchTopical4 g/100g
LiquidIntrathoracic; Subcutaneous1 %
GelTopical2.36 g/59g
SprayTopical2.36 g/59g
GelTopical5 %
GelTopical5 g/100g
GelTopical4 g/100mL
SprayTopical2.5 g/100mL
GelTopical2.5 %
GelTopical
CreamTopical1 %
SolutionTopical0.5 %
SprayTopical0.5 %
CreamTopical2 g/mL
CreamTopical4 g/mL
InjectionInfiltration10 mg/mL
Injection, solutionInfiltration; Perineural
Injection, solutionInfiltration; Perineural10 mg/mL
Injection, solutionInfiltration; Perineural20 mg/mL
Injection, solutionInfiltration; Perineural5 mg/mL
JellyTopical.5 mg/18mL
LiquidIntraspinal
LiquidInfiltration5 mg
SolutionEpidural15 mg
LiquidInfiltration20 mg
SolutionEpidural20 mg
SolutionEpidural
LiquidSubarachnoid50 mg
SolutionEpidural; Infiltration17.3 mg
SolutionOral100 mg
Injection, solutionEpidural; Infiltration; Intracaudal; Perineural
Injection, solutionEpidural; Infiltration; Intracaudal; Perineural15 mg/mL
Injection, solutionInfiltration5 mg/mL
LiquidIntraspinal; Percutaneous1 %
LiquidPercutaneous1 %
LiquidEpidural
LiquidInfiltration1 %
AerosolOral; Topical
SprayTopical40 mg
LiquidTopical50 mg
LiquidOral; Topical20 mg
SolutionRetrobulbar; Topical40 mg/mL
LiquidEpidural; Intracaudal20 mg
SolutionIntravenous100 mg
LiquidIntravenous200 mg
Aerosol, metered; sprayTopical
LiquidTopical2.5 %
SolutionTopical4.0 %
PowderIntradermal.5 mg/1
Prices
Unit descriptionCostUnit
Rocephin 10 gm vial478.32USD each
Lidocaine HCl 3% Lotion 177ml Bottle230.3USD bottle
Rocephin 2 gm vial97.5USD each
Rocephin 1 gm vial62.02USD each
EMLA 2.5-2.5% Cream 30 gm Tube58.4USD tube
Lidocaine-Prilocaine 2.5-2.5% Cream 30 gm Tube47.79USD tube
Lidocaine HCl 2% Gel 10ml Syringe17.99USD syringe
Lidocaine HCl 2% Gel 30ml Tube17.99USD tube
Lidocaine HCl 4% Solution 50ml Bottle16.99USD bottle
Lidocaine Viscous 2% Solution 100ml Bottle13.99USD bottle
Lidocaine hcl 1% syringe9.76USD ml
Lidocaine HCl 4% Solution 4ml Bottle9.42USD bottle
Lidoderm 1 Box = 30 Patches8.03USD patch
Akten 3.5% drops7.5USD ml
Lidocaine 5% in d7.5w ampul3.06USD ml
Lidocaine 3% cream2.91USD g
Lidamantle 3% cream2.03USD g
Zilactin-l cold sore liquid0.99USD ml
Xylocaine 2% jelly0.68USD ml
Lidocaine hcl 10% vial0.55USD ml
Xylocaine 5% ointment0.42USD g
Xylocaine Jelly 2 % Jelly0.41USD g
Xylocaine 2% Solution0.34USD ml
Xylocaine 5 % Ointment0.29USD g
Lidocaine HCl 1% Solution0.24USD ml
Lidocaine hcl powder0.24USD g
Lidocaine base powder0.22USD g
Lidocaine hcl 4% solution0.18USD ml
Xylocaine 0.5% vial0.18USD ml
Lidodan 5 % Ointment0.16USD g
Xylocaine Viscous 2 % Liquid0.1USD ml
Lidocaine hcl 0.5% vial0.08USD ml
Solarcaine aerosol0.06USD g
Lidodan Viscous 2 % Liquid0.06USD ml
Lidocaine 2% viscous solution0.03USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5234957No1994-02-272011-02-27Us
US5827529No1995-10-272015-10-27Us
US8540665No2009-10-222029-10-22Us
US6881200No1996-06-112016-06-11Us
US6004286No1997-03-172017-03-17Us
US5899880No1996-05-042016-05-04Us
US6031007No1997-04-012017-04-01Us
US6629968No2000-06-302020-06-30Us
US6635045No2001-06-292021-06-29Us
US6546281No1995-07-282015-07-28Us
US5658583No1995-07-282015-07-28Us
US6465006No1995-07-282015-07-28Us
US6465709No2000-07-072020-07-07Us
US6780426No1995-07-282015-07-28Us
US6306431No1995-07-282015-07-28Us
US5919479No1995-07-282015-07-28Us
US6528086No1999-09-282019-09-28Us
US8759401No2006-07-242026-07-24Us
US9370622No2015-09-282035-09-28Us
US9358338No2015-04-272035-04-27Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)68.5 °CPhysProp
boiling point (°C)159-160 °C at 2.00E+00 mm HgPhysProp
water solubility4100 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.44AVDEEF,A (1997)
logS-1.76ADME Research, USCD
Caco2 permeability-4.21ADME Research, USCD
pKa8.01SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.593 mg/mLALOGPS
logP1.81ALOGPS
logP2.84ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)13.78ChemAxon
pKa (Strongest Basic)7.75ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.34 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity73.93 m3·mol-1ChemAxon
Polarizability27.77 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Download (7.18 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-000i-9000000000-38a47958df650b972703
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0090000000-7a90fe8d9b35b745cfce
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0920000000-f9f648594c0f1642cc4c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0089-0900000000-5716ccc63e48696473bc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-9d18ae1cd0a81ee63d35
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0090000000-83bc5908a67b3ba4b826
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-8090000000-e305bfb01d615662d8a1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-eab27554002663b2d3fd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-1b684e31ff74300b808f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-b39af34b526d79a4b07b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-9466a1403df493f5b6e9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0090000000-c773b8e10c70518882c1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-8090000000-00b6d0139ebe20cdb189
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-0b33ce49934844438e43
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-502494c9626d1dca25d1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-b39af34b526d79a4b07b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-86c007695ec40849f993
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-7f630b7fa4e36c59e0d2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-9060000000-b5aef137d8e488097fc4
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-9000000000-b21ee69ce889ba36b5e5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-9000000000-9d7555c18e41a90508a5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-0090000000-3dd6e01da50ad1a66b2f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-9230000000-577ea8a290877187b518
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-9000000000-3f33ed4d35a979dbd732
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-9000000000-343e9e6a26be64016b15
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-9000000000-c1923c77757d099538dd
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000i-9000000000-9ff21e9bcf3f87f70774
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-eaebad6c7c4ce7832c9c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-2e21612ecf5a40923bb5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9050000000-930a3c8f94fdb363cc0f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-9000000000-bc7800eef651a1a0ee2c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-9000000000-a658a8aeac537602e1a7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-9000000000-5a056c9766b47a19f0a2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-9000000000-d649b0b05937216241a6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-6090000000-31a60a2cff302fde1ad8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-9020000000-da68f84a1fd4a905c98c
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as m-xylenes. These are aromatic compounds that contain a m-xylene moiety, which is a monocyclic benzene carrying exactly two methyl groups at the 1- and 3-positions.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Xylenes
Direct Parent
m-Xylenes
Alternative Parents
Trialkylamines / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
Substituents
M-xylene / Tertiary aliphatic amine / Tertiary amine / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidic acid derivative / Carboximidic acid / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amino compound, monocarboxylic acid amide, benzenes (CHEBI:6456)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
Gene Name
SCN10A
Uniprot ID
Q9Y5Y9
Uniprot Name
Sodium channel protein type 10 subunit alpha
Molecular Weight
220623.605 Da
References
  1. Ekberg J, Jayamanne A, Vaughan CW, Aslan S, Thomas L, Mould J, Drinkwater R, Baker MD, Abrahamsen B, Wood JN, Adams DJ, Christie MJ, Lewis RJ: muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):17030-5. Epub 2006 Oct 31. [PubMed:17077153]
  2. Muroi Y, Chanda B: Local anesthetics disrupt energetic coupling between the voltage-sensing segments of a sodium channel. J Gen Physiol. 2009 Jan;133(1):1-15. doi: 10.1085/jgp.200810103. Epub 2008 Dec 15. [PubMed:19088384]
  3. Karoly R, Lenkey N, Juhasz AO, Vizi ES, Mike A: Fast- or slow-inactivated state preference of Na+ channel inhibitors: a simulation and experimental study. PLoS Comput Biol. 2010 Jun 17;6(6):e1000818. doi: 10.1371/journal.pcbi.1000818. [PubMed:20585544]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN9A
Uniprot ID
Q15858
Uniprot Name
Sodium channel protein type 9 subunit alpha
Molecular Weight
226370.175 Da
References
  1. Sheets PL, Jackson JO 2nd, Waxman SG, Dib-Hajj SD, Cummins TR: A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity. J Physiol. 2007 Jun 15;581(Pt 3):1019-31. Epub 2007 Apr 12. [PubMed:17430993]
  2. Muroi Y, Chanda B: Local anesthetics disrupt energetic coupling between the voltage-sensing segments of a sodium channel. J Gen Physiol. 2009 Jan;133(1):1-15. doi: 10.1085/jgp.200810103. Epub 2008 Dec 15. [PubMed:19088384]
  3. Karoly R, Lenkey N, Juhasz AO, Vizi ES, Mike A: Fast- or slow-inactivated state preference of Na+ channel inhibitors: a simulation and experimental study. PLoS Comput Biol. 2010 Jun 17;6(6):e1000818. doi: 10.1371/journal.pcbi.1000818. [PubMed:20585544]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN5A
Uniprot ID
Q14524
Uniprot Name
Sodium channel protein type 5 subunit alpha
Molecular Weight
226937.475 Da
References
  1. Itoh H, Tsuji K, Sakaguchi T, Nagaoka I, Oka Y, Nakazawa Y, Yao T, Jo H, Ashihara T, Ito M, Horie M, Imoto K: A paradoxical effect of lidocaine for the N406S mutation of SCN5A associated with Brugada syndrome. Int J Cardiol. 2007 Oct 18;121(3):239-48. Epub 2007 Apr 18. [PubMed:17445919]
  2. Fedida D, Orth PM, Hesketh JC, Ezrin AM: The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol. 2006 May;17 Suppl 1:S71-S78. [PubMed:16686685]
  3. Wallace CH, Baczko I, Jones L, Fercho M, Light PE: Inhibition of cardiac voltage-gated sodium channels by grape polyphenols. Br J Pharmacol. 2006 Nov;149(6):657-65. Epub 2006 Oct 3. [PubMed:17016511]
  4. Cerne A, Bergh C, Borg K, Ek I, Gejervall AL, Hillensjo T, Olofsson JI, Stener-Victorin E, Wood M, Westlander G: Pre-ovarian block versus paracervical block for oocyte retrieval. Hum Reprod. 2006 Nov;21(11):2916-21. Epub 2006 Jul 13. [PubMed:16840798]
  5. Muroi Y, Chanda B: Local anesthetics disrupt energetic coupling between the voltage-sensing segments of a sodium channel. J Gen Physiol. 2009 Jan;133(1):1-15. doi: 10.1085/jgp.200810103. Epub 2008 Dec 15. [PubMed:19088384]
  6. Karoly R, Lenkey N, Juhasz AO, Vizi ES, Mike A: Fast- or slow-inactivated state preference of Na+ channel inhibitors: a simulation and experimental study. PLoS Comput Biol. 2010 Jun 17;6(6):e1000818. doi: 10.1371/journal.pcbi.1000818. [PubMed:20585544]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ubiquitin protein ligase binding
Specific Function
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TG...
Gene Name
EGFR
Uniprot ID
P00533
Uniprot Name
Epidermal growth factor receptor
Molecular Weight
134276.185 Da
References
  1. Sakaguchi M, Kuroda Y, Hirose M: The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor. Anesth Analg. 2006 Apr;102(4):1103-7. [PubMed:16551906]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated sodium channel activity
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN4A
Uniprot ID
P35499
Uniprot Name
Sodium channel protein type 4 subunit alpha
Molecular Weight
208059.175 Da
References
  1. Leuwer M, Haeseler G, Hecker H, Bufler J, Dengler R, Aronson JK: An improved model for the binding of lidocaine and structurally related local anaesthetics to fast-inactivated voltage-operated sodium channels, showing evidence of cooperativity. Br J Pharmacol. 2004 Jan;141(1):47-54. Epub 2003 Dec 8. [PubMed:14662728]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Herve F, Duche JC, d'Athis P, Marche C, Barre J, Tillement JP: Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. [PubMed:8946472]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various hydrophobic ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and ava...
Gene Name
ORM2
Uniprot ID
P19652
Uniprot Name
Alpha-1-acid glycoprotein 2
Molecular Weight
23602.43 Da
References
  1. Herve F, Duche JC, d'Athis P, Marche C, Barre J, Tillement JP: Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. [PubMed:8946472]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, Kivisto KT: Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000 Aug;28(8):959-65. [PubMed:10901707]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, Kivisto KT: Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000 Aug;28(8):959-65. [PubMed:10901707]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. [PubMed:11160873]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603. [PubMed:11743742]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13